Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PGEN
SellHot AirPrecigen, Inc. · Healthcare · United States · $2.5B · Avg Vol: $36M/d
COMPANY DESCRIPTION
Precigen, Inc. is a biotechnology company developing gene and cell therapies to address unmet needs in oncology, autoimmune disorders, and infectious diseases, utilizing its advanced genomic engineering platform. The company's competitive moat is based on its proprietary UltraCAR-T and AdenoVerse technologies designed for rapid, flexible, and cost-effective therapeutic development. It aims to be a leader in the next generation of precision medicines.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.9M | 6.2M | 3.9M | 9.7M | -28.9% | 85.7M | 233.0M | 454.4M | 585.0% |
| EPS | 0.14 | -0.39 | -0.47 | -1.37 | — | -1.07 | — | — | — |
| Shares | 208.2M | 248.9M | 292.9M | 353.9M | +70.0% | 358.0M | — | — | — |
| Debt | 51.4M | 7.1M | 5.5M | 98.3M | 24.1% | 98.3M | — | — | — |
| Equity | 126.3M | 118.5M | 38.5M | 20.9M | -45.1% | — | — | — | — |
| Op CF | -65.0M | -66.9M | -68.2M | -87.8M | — | -114.2M | — | — | — |
| Inv CF | 226.4M | -3.1M | -20.7M | -1.5M | — | — | — | — | — |
| Fin CF | -155.3M | 29.6M | 110.6M | 90.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PGEN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PGEN | Precigen, Inc.(you) | $2.5B | 28 | Sell |
| TRVI | Trevi Therapeutics, Inc. | $2.4B | 28 | Sell |
| NRIX | Nurix Therapeutics, Inc. | $2.7B | 28 | Sell |
| NUVB | Nuvation Bio Inc. | $2.3B | 31 | Sell |
| ZYME | Zymeworks Inc. | $2.0B | 28 | Sell |
| MBX | MBX Biosciences, Inc. | $3.0B | 28 | Sell |
| NKTR | Nektar Therapeutics | $2.5B | 23 | Sell |
| VIR | Vir Biotechnology, Inc. | $1.8B | 29 | Sell |
| ATAI | AtaiBeckley Inc. | $2.7B | 23 | Sell |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.8B | 24 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%